Dendale R, Thariat J, Doyen J, Balosso J, Stefan D, Bolle S, Feuvret L, Poortmans P, Hannoun-Lévi J-M, Bondiau P-Y, Micaud M, Alapetite C, Calugaru V, Habrand J-L, Mahé M-A
Department of radiation oncology, institut Curie, centre de protonthérapie d'Orsay, bâtiment 101, campus universitaire d'Orsay, 91898 Orsay cedex, France.
Department of Radiation Oncology, centre François-Baclesse, 3, avenue General-Harris, 14000 Caen, France; Association Advanced Resource Center for HADrontherapy in Europe (Archade), 3, avenue General-Harris, 14000 Caen, France; Normandie université, 14000 Caen, France; Laboratoire de physique corpusculaire IN2P3/UMR6534, Ensicaen, 14000 Caen, France.
Cancer Radiother. 2019 Oct;23(6-7):617-624. doi: 10.1016/j.canrad.2019.07.129. Epub 2019 Aug 30.
Among over 100 proton therapy centres worldwide in operation or under construction, French proton therapy is coming to full maturity with the recent opening of the Nice (1991, upgrade in 2016) and Caen (2018) facilities next to the Orsay (1991, upgrade in 2010) centre. Proton therapy is a national priority for children and young adults in all three centres. The patient-related activity of the three French centres is coordinated via the Protonshare portal to optimise referral by type of indication and available expertise in coordination with the French society of radiation oncology SFRO and French radiotherapy centres. The centres are recognised by the French Health Care excellence initiative, promoted by the ministry of Foreign Affairs. The three centres collaborate structurally in terms of clinical research and are engaged at the international level in the participation to European databases and research initiatives. Concerted actions are now also promoted in preclinical research via the Radiotransnet network. Ongoing French developments in proton therapy are well presented in international hadron therapy meetings, including European Proton Therapy Network and Particle Therapy Cooperative Oncology Group. Proton therapy teaching in France is offered at several levels and is open to colleagues from all radiation oncology centres, so that they are fully informed, involved and trained to facility recognition of possible indications and thereby to contribute to appropriate patient referral. This close collaboration between all actors in French radiation oncology facilitates the work to demonstrate the required level of medical and scientific evidence for current and emerging indications for particle therapy. Based on that, the future might entail a possible creation of more proton therapy facilities in France.
在全球100多家正在运营或建设中的质子治疗中心中，随着最近尼斯（1991年开业，2016年升级）和卡昂（2018年开业）设施的启用，以及奥赛（1991年开业，2010年升级）中心的存在，法国的质子治疗正走向全面成熟。质子治疗是这三个中心针对儿童和青年的国家优先事项。法国这三个中心与患者相关的活动通过Protonshare门户网站进行协调，以便根据适应症类型和现有专业知识，与法国放射肿瘤学会SFRO及法国放疗中心合作，优化转诊。这些中心获得了由外交部推动的法国医疗卓越计划的认可。这三个中心在临床研究方面进行了结构性合作，并在国际层面参与欧洲数据库和研究倡议。目前还通过Radiotransnet网络在临床前研究中推动协同行动。法国在质子治疗方面的持续进展在国际强子治疗会议上得到了充分展示，包括欧洲质子治疗网络和粒子治疗协作肿瘤学组。法国的质子治疗教学在多个层面开展，并向所有放射肿瘤中心的同事开放，以便他们充分了解、参与并接受培训，以识别可能的适应症，从而为适当的患者转诊做出贡献。法国放射肿瘤学所有参与者之间的这种密切合作有助于开展工作，以证明粒子治疗当前和新出现适应症所需的医学和科学证据水平。基于此，未来法国可能会创建更多的质子治疗设施。
